Literature DB >> 26823621

Secukinumab.

Dennis J Cada1, Danial E Baker2, Shannon G Panther3, Kyle Ingram PharmD4.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The September 2015 monograph topics are cangrelor, lumacaftor/ivacaftor, brexpiprazole, talimogene laherparepvec, and lesinurad. The Safety MUE is on cangrelor.

Entities:  

Year:  2015        PMID： 26823621      PMCID： PMC4686478          DOI： 10.1310/hpj5008-714

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  22 in total

1.  Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.

Authors:  Mark C Genovese; Patrick Durez; Hanno B Richards; Jerzy Supronik; Eva Dokoupilova; Vadim Mazurov; Jacob A Aelion; Sang-Heon Lee; Christine E Codding; Herbert Kellner; Takashi Ikawa; Sophie Hugot; Shephard Mpofu
Journal:  Ann Rheum Dis       Date:  2012-06-23       Impact factor: 19.103

Review 2.  Unmet needs in the treatment of psoriasis.

Authors:  Knud Kragballe; Peter C M van de Kerkhof; Kenneth B Gordon
Journal:  Eur J Dermatol       Date:  2014 Sep-Oct       Impact factor: 3.328

3.  Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).

Authors:  A Blauvelt; J C Prinz; A B Gottlieb; K Kingo; H Sofen; M Ruer-Mulard; V Singh; R Pathan; C Papavassilis; S Cooper
Journal:  Br J Dermatol       Date:  2014-12-11       Impact factor: 9.302

4.  Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.

Authors:  Mamitaro Ohtsuki; Akimichi Morita; Masatoshi Abe; Hidetoshi Takahashi; Noriko Seko; Alexander Karpov; Tomohiro Shima; Charis Papavassilis; Hidemi Nakagawa
Journal:  J Dermatol       Date:  2014-10-30       Impact factor: 4.005

5.  Consensus guidelines for the management of plaque psoriasis.

Authors:  Sylvia Hsu; Kim Alexander Papp; Mark G Lebwohl; Jerry Bagel; Andrew Blauvelt; Kristina Callis Duffin; Jeffrey Crowley; Lawrence F Eichenfield; Steven R Feldman; David F Fiorentino; Joel M Gelfand; Alice B Gottlieb; Carmen Jacobsen; Robert E Kalb; Arthur Kavanaugh; Neil J Korman; Gerald G Krueger; Melissa A Michelon; Warwick Morison; Christopher T Ritchlin; Linda Stein Gold; Stephen P Stone; Bruce E Strober; Abby S Van Voorhees; Stefan C Weiss; Karolyn Wanat; Bruce F Bebo
Journal:  Arch Dermatol       Date:  2012-01

Review 6.  Effect of IL-17A blockade with secukinumab in autoimmune diseases.

Authors:  Dhavalkumar D Patel; David M Lee; Frank Kolbinger; Christian Antoni
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

7.  Secukinumab in plaque psoriasis--results of two phase 3 trials.

Authors:  Richard G Langley; Boni E Elewski; Mark Lebwohl; Kristian Reich; Christopher E M Griffiths; Kim Papp; Lluís Puig; Hidemi Nakagawa; Lynda Spelman; Bárður Sigurgeirsson; Enrique Rivas; Tsen-Fang Tsai; Norman Wasel; Stephen Tyring; Thomas Salko; Isabelle Hampele; Marianne Notter; Alexander Karpov; Silvia Helou; Charis Papavassilis
Journal:  N Engl J Med       Date:  2014-07-09       Impact factor: 91.245

8.  Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.

Authors:  Iain B McInnes; Joachim Sieper; Jürgen Braun; Paul Emery; Désirée van der Heijde; John D Isaacs; Georg Dahmen; Jürgen Wollenhaupt; Hendrik Schulze-Koops; Joseph Kogan; Shenglin Ma; Martin M Schumacher; Arthur P Bertolino; Wolfgang Hueber; Paul P Tak
Journal:  Ann Rheum Dis       Date:  2013-01-29       Impact factor: 19.103

9.  Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds.

Authors:  Vibeke Strand; Mark Kosinski; Ari Gnanasakthy; Usha Mallya; Shephard Mpofu
Journal:  Health Qual Life Outcomes       Date:  2014-03-05       Impact factor: 3.186

Review 10.  Targeting of interleukin-17 in the treatment of psoriasis.

Authors:  Ann Sophie Lønnberg; Claus Zachariae; Lone Skov
Journal:  Clin Cosmet Investig Dermatol       Date:  2014-09-15
View more
  1 in total

Review 1.  Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.

Authors:  Pim Aarts; Koen Dudink; Allard R J V Vossen; Kelsey R van Straalen; Christine B Ardon; Errol P Prens; Hessel H van der Zee
Journal:  Drugs       Date:  2021-07-20       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.